ADC Therapeutics raises $100 million in private placement

ADC Therapeutics (ADCT) has secured $100 million in PIPE financing, selling shares at $3.53 and warrants at $3.43, led by Redmile Group, to support the clinical development and commercialization of ZYNLONTA. As part of a restructuring, ADCT will discontinue certain preclinical programs, close its UK facility, and reduce its global workforce by 30%, expecting to extend its cash runway into 2028. Despite a negative EBITDA of -$124 million, analysts remain optimistic with price targets ranging from $7 to $10, citing promising LOTIS-7 Phase 1b trial results and upcoming data from LOTIS-5 Phase 3 trial.

Analysis

ADC Therapeutics SA (ADCT) has secured a critical $100 million through a private investment in public equity (PIPE) financing, selling 13 million common shares at $3.53 per share and 15.7 million pre-funded warrants at $3.43 per warrant. This financing, led by Redmile Group and expected to close on June 16, arrives as the company navigates a challenging financial landscape, evidenced by a negative EBITDA of -$124 million over the last twelve months, despite its stock surging over 78% in the past six months. The proceeds are earmarked primarily for the clinical development and commercialization of its FDA accelerated-approved cancer drug ZYNLONTA, and to advance its preclinical exatecan-based ADC targeting PSMA. Concurrently, ADCT is undergoing a significant restructuring, which includes discontinuing other early preclinical programs, closing its UK facility, and reducing its global workforce by approximately 30% by September 30, incurring $6 million to $7 million in one-time cash charges. These measures are projected to extend the company's cash runway into 2028 and reduce operating expenses. Despite rapidly depleting cash reserves, InvestingPro data indicates a strong current ratio of 4.46, suggesting sufficient liquidity to manage these restructuring costs. Recent Q4 2024 earnings presented a mixed picture: an EPS of -$0.25 beat analyst expectations of -$0.43, but revenue of $16.91 million and ZYNLONTA sales of $16.4 million fell short of consensus estimates of $18.85 million and $19.1 million, respectively. This led Guggenheim Securities to lower its price target to $7 from $10, though maintaining a Buy rating, while RBC Capital Markets reiterated an Outperform rating with an $8 target, citing optimism for ZYNLONTA. Promisingly, the LOTIS-7 Phase 1b trial combining ZYNLONTA with glofitamab showed a 93.3% overall response rate in relapsed/refractory DLBCL patients, with key data from this trial expected in H2 2025 and topline results from the LOTIS-5 Phase 3 confirmatory trial anticipated in late 2025 or H1 2026.

Key Decisions for Investors

• Investors should acknowledge the near-term dilution from the PIPE financing, priced at $3.53 for shares and $3.43 for warrants, but recognize the crucial extension of the cash runway into 2028 this provides for key clinical and commercial activities.
• Monitor upcoming clinical milestones closely, particularly data from the LOTIS-7 Phase 1b trial in H2 2025 and topline results from the LOTIS-5 Phase 3 trial in late 2025/H1 2026, as these will be significant catalysts for ZYNLONTA's future and ADCT's valuation.
• Assess the company's ability to execute its restructuring plan effectively, managing the $6-7 million in charges and realizing projected cost savings, while closely tracking ZYNLONTA's commercial performance given the recent sales miss against analyst expectations.
• Consider the balance between the promising preliminary efficacy data from combination trials like LOTIS-7 and the ongoing commercial challenges and financial burn rate when evaluating positions, noting analyst price targets range from $7 to $10 despite recent target adjustments.